Clinical Research

At CLS Health, we are striving to bring new and advanced treatment opportunities to our patients.

For more than 12 years the physicians of CLS Health have partnered with over 100 clinical trials to aid in the development or new treatment options for our patients. Study visits are conducted within the comfort of our practice office(s) with our partner Tranquil Clinical Research. Together, our Clinical Research Trials are research studies designed to test the safety and effectiveness of new medications and treatments.

 

Open CLS Health Studies

How to Participate 

Participants undergo careful pre-screening and screening steps before they are enrolled in a study. Screening consists of review of information such as: age, previous treatments, and other medical conditions to ensure the most appropriate patient is enrolled into the study. 

Eligible participants meet with one of our highly trained research staff to review the study and answer any and all questions. Our research staff’s number one job is to ensure the rights, safety and wellness of our participants is protected and maintained throughout your participation in the study. An informed consent is a document that has been approved by an independent review board (IRB) and is reviewed and signed by each participant prior to the conduct of any study procedures. 

Participation in a clinical trial incurs at no cost to the participant for anything conducted specifically for the study. The study sponsor may also offer compensation for time and travel. Information regarding risks, benefits, your responsibilities, compensation, the reason for the study and more will be discussed during the informed consent review. 

Study participation is voluntary. Participants may withdraw from study participation at any time. The decision to withdraw will not result in any penalty nor adversely affect your relationship with your study doctor or practitioner. 

HYPOTHYROIDISM STUDY 

Do you suffer from Hypothyroidism?  Researchers are studying an investigational product to assess its effects on your thyroid hormone levels and quality of life. 

Qualifications: 

  • Are between 18 and 75 years old 
  • Have been diagnosed with primary hypothyroidism 
  • Have been on continuous thyroid replacement therapy with levothyroxine for at least 12 months 

Requirements 

  • You will receive study treatment 
  • There will be 12 visits with your doctor 
  • You will be compensated for your time for study visits and laboratory sample collections 

Contact Us NOW Space is Limited: 

 

LUNG BIO STUDY 

Have you been diagnosed with Pulmonary Hypertension due to COPD? 

Qualifications: 

  • Be 18 years or older 
  • Must have an established diagnosis of chronic obstructive pulmonary disease (COPD) with suspected or confirmed pulmonary hypertension 
  • Must be able to walk at least 100 meters during a 6-minute walk test without limitations in mobility using no oxygen, or oxygen at no more than 10 liters per minute 
  • Willing and able to use Sponsor provided devices (actigraph, spirometer, and smart device) 

Requires: 

  • Inhaled Treprostinil for PH-COPD 
  • Willing to undergo Right Heart Catheterization 

Contact Us NOW Space is Limited: 

  • Tranquil Clinical Research 
  • Call 713-907-6054 
  • There will be compensation for your time 

Click here for more information regarding this study or call 713-907-6054 

Lung Bio PERFECT Study Information 

 

FSGS STUDY 

FSGS is a type of kidney disease that occurs when scar tissue develops on the parts of your kidneys that act as filters (the glomeruli). The scar tissue makes it more difficult for the filters to do their job. Instead of keeping essential proteins in your body, the injured filters allow these proteins to flow into the urine. This can lead to high levels of protein in your urine, a condition called proteinuria. Podocytes are cells lining the kidney that, in their normal state, prevent proteinuria. Injury to, and loss of, podocytes is a central component of FSGS. Protecting podocytes from further injury, and stopping proteinuria, may help slow the progression of kidney disease and potentially prevent kidney failure. 

What is the purpose of this trial?
Currently, there is no approved therapy in the US to treat Focal Segmental Glomerulosclerosis (FSGS). Advances in drug therapy are key to treating FSGS in its early stages and preventing further kidney damage. The TRACTION-2 Trial is testing an investigational medication (GFB-887) that has the potential to reduce the amount of protein in urine and preserve kidney function in patients with kidney disease. If you have FSGS, this trial may be an option for you. 

Qualifications:  

  • Are 18 to 75 years of age 
  • Have been diagnosed or are being treated for FSGS 
  • Have high levels of protein in your urine (proteinuria) 

Requires: 

  • Diagnosis based on documented biopsy or genetic testing and currently receiving ACE inhibitor or ARB for 3 months 

Contact Us NOW Space is Limited: 

  • There will be compensation for your time 

Click here for more information regarding this study or call 713-907-6054 

FSGS Study Information 

OVER ACTIVE BLADDER STUDY 

Diagnosed with OAB? Participate in a clinical study for a new wearable OAB device 

Qualifications:  

  • Be 18 or older 
  • Diagnosed with Overactive Bladder 
  • Have an average of 11 urinary frequency events per day 
  • Have daily access to WIFI 

Requires: 

  • Wearing an investigational device for 30 minutes 1 to 3 times per week in your home 
  • 12-week study period 

Contact Us NOW Space is Limited: 

  • Tranquil Clinical Research 
  • Call 713-907-6054 
  • There will be compensation for your time 

Click here for more information regarding this study or call 713-907-6054 

Over Active Bladder Clinical Study Information 

 

PEDIATRIC VARICELLA VACCINE STUDY 

This study is looking at different strengths of a potential new investigational vaccine against chickenpox (varicella). The study will look at how safe the study vaccine is and will also determine whether it works to help prevent chickenpox in children. 

Why is this study important? 

Chickenpox is a very contagious infection that can cause serious complications in children.  Access to several chickenpox vaccines is important because vaccination is the only way to help protect children from chickenpox. 

Qualifications: 

Your child may be able to take part if they: 

  • Are 12-15 months of age 
  • Are in good health 
  • Have received the first 3 doses (primary series) of a pneumococcal conjugate vaccine, a vaccine against infections caused by the Streptococcus pneumoniae bacteria, which cause ear, lung, and other infections. 

Requirements 

If your child takes part, they will be in this study for about 6 months. Your child will need to: 

  • Complete 3 study visits and 2 phone contacts for safety follow-up. 
  • Receive the study vaccine or reference vaccine and 3 other approved vaccines that are part of routine vaccination schedules: 
  • M-M-R II against measles, mumps, and rubella 
  • Havrix against hepatitis A infection 
  • Prevnar 13, a pneumococcal conjugate vaccine, against infections caused by the Streptococcus pneumoniae bacteria, which cause ear, lung, and other infections 
  • Have 1 blood sample collected about 6 weeks after vaccination. 

Contact Us NOW Space is Limited: 

  • Tranquil Clinical Research 
  • Call 713-907-6054 
  • There will be compensation for your time 

 

SYSTEMIC LUPUS ERYTHEMATOSUS STUDY 

Systemic Lupus Erythematosus (SLE), also known as “lupus”, is an autoimmune disease that affects multiple organ systems and is unpredictable in disease severity, with periods of illness or flares alternating with periods of remission. The presentation of lupus can affect many different parts of the body, but frequently involves the joints, skin, kidneys, blood cells and mucus membranes (the lining of the mouth, nose, throat, stomach, and intestines) which can result in symptoms such a swollen joints, rash, foamy urine, changes in red or white blood cells, and oral ulcers, among others. Disease prevalence is approximately 1 in 1000 individuals overall but varies with race and ethnicity.  

What is the purpose of this trial?
Most therapies used to treat SLE are only partially effective and have considerable toxicity. The purpose of the study is to investigate if the investigational product, BIIB059, can reduce disease activity and inflammation in people with active SLE compared to a placebo. BIIB059 is a type of antibody that has been developed to target certain cells that are thought to play a role in the development of lupus. It is hoped the study drug can improve symptoms in people who have SLE. 

Qualifications: 

  • Participants must be ≥18 years of age 
  • Have been diagnosed with moderate-to-severe SLE for at least 6 months 
  • Are currently taking SLE medication 

Requirements 

  • You will receive investigational product via injections under the skin every month 
  • Visits will last about a year and a half and include around 22 visits to the study site. 

Contact Us NOW Space is Limited: